Of the biotech industry, the author of today’s article notes that it “has seen its share of losses over the past couple of months but that provides us the perfect opportunity to pick up shares of stocks that could see substantial gains in the months ahead.” With that, he proceeds to highlight three undervalued biotech stocks poised to see their…
The prospect of tighter regulation of the sector (particularly when it comes to mergers and drug approvals) and drug-pricing reform, as well as rising interest rates, have created a “perfect storm” bearing down on biotech stocks. As a result, after seeing massive gains in 2020, biotech stocks have pulled back. Do biotech investors have reason to worry, or is biotech’s…
“The kinds of biotechs best for investors who aren’t huge risk-takers are those that generate solid revenue growth, are profitable (or soon will be), and have promising pipelines,” advises the author of today’s article, who proceeds to highlight three stocks that appear to match this profile to consider buying this month. For more, CLICK HERE.
A rumored takeover candidate is among the five small-cap biotech stocks trading under $10 highlighted in today’s article, all of which boast Buy ratings from well-known Wall Street firms – and solid upside potential. For these five biotech stocks, which are suited for very aggressive investors, CLICK HERE.
Despite its focus on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, the clinical-stage company featured in today’s article is woefully behind the likes of Pfizer, Moderna, Johnson & Johnson and AstraZeneca when it comes to its COVID-19 product – its lead product. But the real value for this company may come from another product…
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s article of the five stocks he highlights – all of which have Buy ratings at major firms and are trading under the $10 level. For these five stocks –which include an intriguing biotech play with…
With new leadership at the federal agencies that oversee the drug industry, a top Wall Street analyst is warning that the biotech industry and biotech investors “will need to adjust to a different regulatory environment to the one they have enjoyed for the last 5 years” – and has downgraded six pharma stocks due, in part, to the prospect of…
Thanks to her bet on disruptive DNA, Bloomberg named ARK Investment Management’s Cathie Wood the best stock picker of 2020. What does Wood believe are going to be the most disruptive sectors going forward, and what specific companies are working on truly disruptive technologies with the potential to change the course of history? For more – including a look at…
“These five top stocks are all on the BofA Securities US 1 list of top picks. They all are very prominent in their respective silos in the financial and health care sectors, and all are great second-quarter ideas for growth investors with a little bit of risk tolerance looking to rotate capital,” says the author of today’s article of the…
When it comes to creating a useful profile for monster growth stocks, the author of today’s article lays out the following criteria: “gangbusters gains, Buy ratings from the Wall Street analyst corps, and considerable upside for the coming year.” With that, he proceeds to highlight three stocks that meet the profile for monster growth, including one that “puts a different…